|Description||BMS-777607 is a novel prodrug of the dual Met/VEGFR-2 inhibitor.|
|Appearance||white solid powder|
|Synonyms||BMS817378; BMS 817378; BMS-817378; BMS 777607; BMS-777607; BMS777607; ASLAN 002; ASLAN-002; ASLAN002.|
|Current Developer||Simcere and Bristol-Myers Squibb|
AMG 208 is a selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. C-Met encodes the hepatocyte growth factor r...
PF-04136309 is an orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral adminis...
This active molecular is a selective RON receptor tyrosine kinase inhibitor. The RON receptor tyrosine kinase has been reported that it usually overexpressed in...
SGX523 is a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited MET with an IC50 of 4 nmol/L an...
SCR-1481B1, also known as c-Met inhibitor 2, is an effective inhibitor of MET kinase so that probably has anti-tumor activity. It is also found to be an inhibit...
PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor and is susceptible to oncogenic mutations (no activity to Y1230C mutant). It showed ...
MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively and also inhibits Ron a...
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM.